Lamivudine Teva Pharma B.V

Lamivudine, the active ingredient in Lamivudine Teva Pharma B.V., is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats HIV-1 infection and chronic hepatitis B in adults. GNH USA supplies Lamivudine Teva Pharma B.V. as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is used in antiretroviral and antiviral therapy for viral infections affecting the immune and hepatic systems.

- HIV-1 infection: reduces viral load and improves immune function when used in combination regimens. - HIV-2 infection: contributes to viral suppression as part of combination therapy. - Chronic hepatitis B infection: suppresses HBV replication and helps prevent liver disease progression.

Lamivudine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient cranial pain. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools, usually self‑limiting. - Insomnia: difficulty falling or staying asleep. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Lactic acidosis: metabolic disturbance requiring urgent care. - Severe hepatomegaly with steatosis: significant liver enlargement. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: systemic allergic response. - Bone marrow suppression: anemia, neutropenia, or thrombocytopenia.

Before initiating lamivudine therapy, several safety considerations should be addressed.

- Liver function monitoring: assess baseline enzymes and watch for hepatitis flare. - Renal function assessment: adjust dosing in impaired clearance. - Pregnancy counseling: discuss potential risks and benefits with a healthcare provider. - Adherence reinforcement: emphasize importance of consistent dosing to prevent resistance. - Hypersensitivity screening: avoid in patients with known allergic reactions to lamivudine. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lamivudine can interact with other medications, influencing efficacy or toxicity.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of pancreatitis. - Stavudine: combined therapy may enhance mitochondrial toxicity. - Other NRTIs: may lead to additive bone marrow suppression.

Moderate Interactions (Monitor Closely): - Tenofovir: monitor renal function due to combined nephrotoxic potential. - Efavirenz: observe for central nervous system side effects. - Protease inhibitors (e.g., ritonavir): may alter lamivudine plasma levels. - Alcohol: increased hepatic strain warrants caution.